How Targeting the Endocannabinoid System Could Lead to New Treatments for Addiction and Obesity | Research

The takeaway

The endocannabinoid system plays a central role in reward-driven behaviors including substance abuse and overeating, making CB1 receptor modulators promising candidates for future medications.

Read this if you're curious about the connection between cannabis science and potential treatments for addiction or obesity.

Both addiction and obesity involve endocannabinoid system hyperactivity

What the researchers found

This review outlined how the endocannabinoid system regulates reward-driven behaviors that underlie both addiction and obesity. Both conditions involve endocannabinoid system hyperactivity, where the brain's internal cannabinoid signaling is turned up too high.

The authors described how CB1 cannabinoid receptor modulators, drugs that can either block or fine-tune CB1 activity, represented a rational therapeutic approach. The review discussed rimonabant, a CB1 blocker that had shown promise for both smoking cessation and weight loss, as a proof of concept.

The key insight was that rational drug design targeting specific components of the endocannabinoid system (receptors, enzymes, transporters) could potentially produce medications that address the reward-seeking component of addiction and obesity without the broad side effects of older approaches.

Why it matters

Both substance abuse and obesity are major public health challenges with limited pharmacological options. This review articulated a scientific rationale for targeting the endocannabinoid system, which regulates both food intake and drug reward through overlapping neural circuits.

The numbers in context

The review covered endocannabinoid system components including CB1 and CB2 receptors, endogenous ligands (anandamide, 2-AG), and metabolic enzymes (FAAH, MAGL). Rimonabant was discussed as the primary CB1 modulator in clinical development.

How the study worked

This was a narrative review synthesizing the scientific literature on endocannabinoid system pharmacology as it relates to addiction and obesity. The authors focused on translational research connecting basic science to potential clinical applications.

What this study cannot tell us

As a narrative review, it did not systematically assess evidence quality. The review was written before rimonabant's psychiatric side effects led to its market withdrawal, so it presented a more optimistic picture than later evidence supported.

How to read the evidence

This is a narrative review that synthesizes the pharmacological rationale for targeting the endocannabinoid system, drawing on animal studies and early clinical trial data.

When this study was published

Published in 2007, before rimonabant was withdrawn from markets in 2008 due to psychiatric side effects. The field has since shifted toward more targeted approaches.

The bigger picture

While the specific drug discussed (rimonabant) was later withdrawn due to psychiatric side effects, the underlying principle that the endocannabinoid system regulates reward and appetite has remained central to ongoing drug development. Newer approaches target enzymes rather than receptors to avoid the psychiatric side effects.

Questions still open

Can endocannabinoid system modulators be developed that avoid the psychiatric side effects that derailed rimonabant? Would partial CB1 antagonists or enzyme inhibitors offer safer therapeutic profiles?

Common questions

What happened to rimonabant?

Rimonabant, the CB1 blocker discussed in this review, was approved in Europe in 2006 for weight loss but was withdrawn in 2008 after reports of serious psychiatric side effects including depression and suicidal thoughts.

Why are addiction and obesity linked through the endocannabinoid system?

Both involve the brain's reward circuitry, where the endocannabinoid system acts as a key regulator. The same CB1 receptors that influence drug reward also control food reward and appetite, which is why blocking them affected both behaviors.

Read the original research

Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.

Current psychiatry reports, 9(5), 365-73

View on PubMed ↗

Citation

Janero, David R; Makriyannis, Alexandros. (2007). Targeted modulators of the endogenous cannabinoid system: future medications to treat addiction disorders and obesity.. Current psychiatry reports, 9(5), 365-73.